Table 1 Association between clinical characteristic parameters and the expression SAMD13 of HCC patients in TCGA

Sex (n = 412)

 Normal (n = 50)

0–0.363 (0.142)

 Male (n = 245)

0–1.311 (0.229)

 < 0.001*

 Female (n = 117)

1–1.159 (0.222)

 < 0.001*

Age (n = 408)

 Normal (n = 50)

0–0.186 (0.142)

 Tumor (21–40, n = 27)

0.062–1.066 (0.271)

 < 0.003

 Tumor (41–60, n = 140)

0–1.287 (0.234)

 < 0.001*

 Tumor (61–80, n = 181)

0–1.25 (0.204)

 < 0.001*

 Tumor (> 80, n = 10)

0.028–1.031 (0.424)

0.004*

Race (n = 401)

 Normal (n = 50)

0–0.363 (0.142)

 Caucasian (n = 177)

0–1.159 (0.211)

 < 0.001*

 African–American (n = 17)

0–0.651 (0.237)

0.017*

 Asian (n = 157)

0–1.394 (0.244)

 < 0.001*

Tumor stage (n = 390)

 Normal (n = 50)

0–0.363 (0.142)

 Stage I (n = 168)

0–1.008 (0.176)

 < 0.001*

 Stage II (n = 84)

0.026–1.394 (0.255)

 < 0.001*

 Stage III (n = 82)

0–1.887 (0.374)

 < 0.001*

 Stage IV (n = 6)

0.027–0.581 (0.304)

n.s

Tumor grade (n = 407)

 Normal (n = 50)

0–0.363 (0.412)

 Grade I (n = 54)

0–0.979 (0.222)

0.001*

 Grade II (n = 173)

0–1.311 (0.214)

 < 0.001*

 Grade III (n = 118)

0–1.268 (0.232)

 < 0.001*

 Grade IV (n = 12)

0.042–1.287 (0.429)

0.017*

Histological subtype (n = 421)

 Normal (n = 50)

0–0.307 (0.141)

 Hepatocellular carcinoma (n = 361)

0–1.268 (0.223)

 < 0.001*

 Fibrolamellar carcinoma (n = 3)

0.055–2.932 (0.979)

0.046*

 Hepatocholangiocarcinoma (Mixed) (n = 7)

0.13–0.378 (0.142)

n.s